| Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies YZ Jiang, D Ma, C Suo, J Shi, M Xue, X Hu, Y Xiao, KD Yu, YR Liu, Y Yu, ... Cancer cell 35 (3), 428-440. e5, 2019 | 682 | 2019 |
| Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study SJ O'Day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ... Annals of Oncology 21 (8), 1712-1717, 2010 | 622 | 2010 |
| Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality V Vinh-Hung, C Verschraegen Journal of the National Cancer Institute 96 (2), 115-121, 2004 | 510 | 2004 |
| Incidence and survival rates for female malignant germ cell tumors HO Smith, M Berwick, CF Verschraegen, C Wiggins, L Lansing, CY Muller, ... Obstetrics & Gynecology 107 (5), 1075-1085, 2006 | 417 | 2006 |
| Gynaecological cancers in pregnancy P Morice, C Uzan, S Gouy, C Verschraegen, C Haie-Meder The Lancet 379 (9815), 558-569, 2012 | 373 | 2012 |
| Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. AP Kudelka, D Tresukosol, CL Edwards, RS Freedman, C Levenback, ... Journal of clinical oncology 14 (5), 1552-1557, 1996 | 324 | 1996 |
| GPR30 predicts poor survival for ovarian cancer HO Smith, H Arias-Pulido, DY Kuo, T Howard, CR Qualls, SJ Lee, ... Gynecologic oncology 114 (3), 465-471, 2009 | 263 | 2009 |
| Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer S Vadhan-Raj, CF Verschraegen, C Bueso-Ramos, HE Broxmeyer, ... Annals of internal medicine 132 (5), 364-368, 2000 | 230 | 2000 |
| Diagnosis, staging, and surveillance of cervical carcinoma H Kaur, PM Silverman, RB Iyer, CF Verschraegen, PJ Eifel, ... American Journal of Roentgenology 180 (6), 1621-1631, 2003 | 212 | 2003 |
| Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20 (s)-camptothecin in patients with advanced pulmonary malignancies CF Verschraegen, BE Gilbert, E Loyer, A Huaringa, G Walsh, RA Newman, ... Clinical Cancer Research 10 (7), 2319-2326, 2004 | 211 | 2004 |
| Ratios of involved nodes in early breast cancer V Vinh-Hung, C Verschraegen, DI Promish, G Cserni, J Van de Steene, ... Breast Cancer Research 6, 1-9, 2004 | 190 | 2004 |
| Vulvar melanoma at the MD Anderson Cancer Center: 25 years later CF Verschraegen, M Benjapibal, W Supakarapongkul, LB Levy, M Ross, ... International Journal of Gynecologic Cancer 11 (5), 2001 | 189 | 2001 |
| A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. AP Kudelka, T Levy, CF Verschraegen, CL Edwards, S Piamsomboon, ... Clinical cancer research: an official journal of the American Association …, 1997 | 189 | 1997 |
| Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. CF Verschraegen, T Levy, AP Kudelka, E Llerena, K Ende, RS Freedman, ... Journal of clinical oncology 15 (2), 625-631, 1997 | 186 | 1997 |
| Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial YZ Jiang, Y Liu, Y Xiao, X Hu, L Jiang, WJ Zuo, D Ma, J Ding, X Zhu, J Zou, ... Cell research 31 (2), 178-186, 2021 | 184 | 2021 |
| Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 AP Kudelka, CF Verschraegen, E Loyer New England Journal of Medicine 338 (14), 991-992, 1998 | 183 | 1998 |
| GnRH antagonists in the treatment of gynecological and breast cancers. G Emons, C Gr, S Westphalen, J Kavanagh, C Verschraegen Endocrine-related cancer 10 (2), 291-299, 2003 | 181 | 2003 |
| Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 Y Ji, C Rankin, S Grunberg, AE Sherrod, J Ahmadi, JJ Townsend, ... Journal of Clinical Oncology 33 (34), 4093, 2015 | 169 | 2015 |
| Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma CF Verschraegen, T Sittisomwong, AP Kudelka, EP Guedes, M Steger, ... Journal of clinical oncology 18 (14), 2733-2739, 2000 | 162 | 2000 |
| Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors W Hu, PD McCrea, M Deavers, JJ Kavanagh, AP Kudelka, ... Clinical & experimental metastasis 18, 83-88, 2000 | 157 | 2000 |
